Aurobindo Pharma Moat Analysis: Score & Risks
Aurobindo Pharma Ltd.
A first-pass moat teardown of Aurobindo Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Aurobindo Pharma Ltd. scores 5.08 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“CuraTeQ has steadfastly built momentum with biosimilar approvals in 2025 and is advancing a robust next-wave pipeline of biosimilars across oncology and immunology segments”
“Leveraging our expertise in process chemistry and the advantages of large-scale production, we have positioned ourselves as a cost-effective provider of API”
“the scales at which we are attempting to become a CMO is a key differentiator in India, right. Now, if you look at my prod”
“Our large product portfolio helps us to maintain optimally the price stability.”
“API business posted revenues decline of 4% YoY impacted primarily by market conditions”
“we will be into the commercial global supply chain right from Day 1 after receiving the regulatory approvals. And that is the business model of TheraNym.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion